Skip to content
ALS News Today logo Newsletter
Newsletter
  • About ALS
    What is ALS?
    Causes and risk factors
    Diagnosis
    Symptoms
    • Speech problems
    • Breathing and swallowing
    • Pseudobulbar affect
    Types of ALS
    • Familial ALS
    • Sporadic ALS
    Living with ALS
    • Mental health
    • Diet
    • Exercise
    • Aids and adaptations
  • Treatments
    Approved treatments
    Experimental treatments
    Non-drug treatments
  • News
  • Columns
    Joyful Sorrow — Kristin Neva
    Living Well With ALS — Dagmar Munn
    Thunder Road — Juliet Taylor
    Archived columns
    • OutSpoken — James Clingman
    • The Mighty Mind — Rachel Doboga
    In memoriam
    • Notes From the ALS Front — Rick Jobus
  • Forums
  • Advocacy partners
  • What can we help you find today?

  • Social Clips
  • Last Week’s Top-3 Most Read Posts On ALS

Last Week’s Top-3 Most Read Posts On ALS

admin avatar

by admin | January 18, 2016

Share this article:

Share article via email
  • Share on Facebook
  • Share on Twitter
  • Share on Reddit
  • Share via Email

Read the Articles Here:

ALS Stem Cell Therapy Seen to Benefit Patients in First Round of Clinical Tests

ALS Patients Show Increased Response to Specific Receptor in Spinal Cord

ALS Severity, Duration May Be Linked to Glutamate Toxicity

 

Print This Page

Tags

glutamate, most read, receptor in spinal cord, stem cell therapy, top 3

Recent Posts

  • AMX0114 receives FDA fast track status for the treatment of ALS
  • Zydus’ usnoflast wins FDA’s fast track drug status for treating ALS
  • Brainstorm taps Minaris to produce NurOwn for Phase 3b trial
  • New ALS scholarship supports US students facing financial barriers
  • Searching for wisdom in the woods as we navigate ALS


Recommended reading

A woman is shown making an announcement using a megaphone.
June 9, 2025 News by Andrea Lobo, PhD

Zydus’ usnoflast wins FDA’s fast track drug status for treating ALS

Two hands are seen clasped in a handshake, denoting a new agreement.
June 6, 2025 News by Lila Levinson, PhD

Brainstorm taps Minaris to produce NurOwn for Phase 3b trial

An illustration shows plants growing from amid a scattering of coins.
June 5, 2025 News by Margarida Maia, PhD

New ALS scholarship supports US students facing financial barriers

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.